编辑精选——直接口服抗凝药在静脉血栓栓塞预防和治疗中的严重出血风险:随机对照试验的网状Meta分析
本研究通过网络Meta分析评估直接口服抗凝药(DOACs)预防和治疗静脉血栓栓塞(VTE)时的严重出血风险,共纳入31项随机对照试验(76 641例患者)。治疗VTE时,阿哌沙班的大出血风险显著低于达比加群(OR 2.10,95%CI 1.07-4.12)和艾多沙班(OR 2.64,95%CI 1.36-5.15);预防VTE时,阿哌沙班的大出血风险显著低于利伐沙班(OR 2.14,95%CI 1.02-4.52)。
要点
- 治疗VTE时,阿哌沙班的大出血和胃肠道出血风险在DOACs中最低。
- 治疗VTE时,利伐沙班的颅内出血风险最低,艾多沙班的致命性出血风险最低。
- 预防VTE时,阿哌沙班在四种出血类型中均为DOACs中出血风险最低。
核心结论
- 治疗VTE时,就大出血和胃肠道出血而言,阿哌沙班的出血风险最低;就颅内出血而言,利伐沙班的出血风险最低;就致命性出血而言,艾多沙班的出血风险最低。
- 预防VTE时,阿哌沙班的出血风险最低。
研究设计与样本
- 检索PubMed、EMBASE、Web of Science和Cochrane Library数据库至2021年1月6日,纳入31项随机对照试验(76 641例患者),采用频率学网状Meta分析。
主要发现
- 治疗VTE时,阿哌沙班的大出血风险显著低于达比加群(OR 2.10,95%CI 1.07-4.12)和艾多沙班(OR 2.64,95%CI 1.36-5.15)。
- 治疗VTE时大出血安全性排名从高到低为:阿哌沙班(SUCRA 98.0)、利伐沙班(SUCRA 69.6)、达比加群(SUCRA 50.7)、艾多沙班(SUCRA 26.5)、维生素K拮抗剂(VKAs;SUCRA 5.1)。
- 治疗VTE时胃肠道出血安全性排名从高到低为:阿哌沙班(SUCRA 80.7)、利伐沙班(SUCRA 66.8)、艾多沙班(SUCRA 62.3)、VKAs(SUCRA 34.4)、达比加群(SUCRA 5.8)。
- 治疗VTE时颅内出血安全性排名从高到低为:利伐沙班(SUCRA 74.4)、艾多沙班(SUCRA 70.4)、达比加群(SUCRA 58.2)、阿哌沙班(SUCRA 44.4)、VKAs(SUCRA 5.6)。
- 治疗VTE时致命性出血安全性排名从高到低为:艾多沙班(SUCRA 82.7)、利伐沙班(SUCRA 59.2)、达比加群(SUCRA 48.6)、阿哌沙班(SUCRA 43.0)、VKAs(SUCRA 16.3)。
关键数值与推荐
- 治疗VTE时,阿哌沙班的大出血风险显著低于达比加群(OR 2.10,95%CI 1.07-4.12)和艾多沙班(OR 2.64,95%CI 1.36-5.15)。
- 预防VTE时,阿哌沙班的大出血风险显著低于利伐沙班(OR 2.14,95%CI 1.02-4.52)。
- 预防VTE时,阿哌沙班在四种出血类型中均为DOACs中出血风险最低:大出血SUCRA 81.6、胃肠道出血SUCRA 75.4、颅内出血SUCRA 64.1、致命性出血SUCRA 73.6。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to determine the severe bleeding safety of direct oral anticoagulants (DOACs) for the prevention and treatment of venous thromboembolism (VTE). METHODS: PubMed, EMBASE, Web of Science, and the Cochrane Library databases were searched up to 6 January 2021. The incidence of severe bleeding (major, gastrointestinal [GI], intracranial, and fatal) was investigated. Using frequentist network meta-analysis, interventions that were not compared directly could be compared indirectly by the 95% confidence interval (CI), making the search results more intuitive. Based on surface under the cumulative ranking curves (SUCRA), the relative ranking probability of each group was generated. RESULTS: Thirty-one randomised controlled trials (76 641 patients) were included. For the treatment of VTE, the risk of major bleeding with apixaban was significantly lower than dabigatran (odds ratio [OR] 2.10, 95% CI 1.07 - 4.12) and edoxaban (OR 2.64, 95% CI 1.36 - 5.15). The safety of the drugs was ranked from highest to lowest as follows: major bleeding: apixaban (SUCRA 98.0), rivaroxaban (SUCRA 69.6), dabigatran (SUCRA 50.7), edoxaban (SUCRA 26.5), and vitamin K antagonists (VKAs; SUCRA 5.1); GI bleeding: apixaban (SUCRA 80.7), rivaroxaban (SUCRA 66.8), edoxaban (SUCRA 62.3), VKAs (SUCRA 34.4), and dabigatran (SUCRA 5.8); intracranial bleeding: rivaroxaban (SUCRA 74.4), edoxaban (SUCRA 70.4), dabigatran (SUCRA 58.2), apixaban (SUCRA 44.4), and VKAs (SUCRA 5.6); fatal bleeding: edoxaban (SUCRA 82.7), rivaroxaban (SUCRA 59.2), dabigatran (SUCRA 48.6), apixaban (SUCRA 43.0), and VKAs (SUCRA 16.3). For the prevention of VTE, the risk of major bleeding with apixaban was significantly lower than rivaroxaban (OR 2.14, 95% CI 1.02 - 4.52). Among the four types of bleeding, apixaban had the lowest bleeding risk among DOACs (major bleeding: SUCRA 81.6; GI bleeding: SUCRA 75.4; intracranial bleeding: SUCRA 64.1; fatal bleeding: SUCRA 73.6). CONCLUSIONS: For the treatment of VTE, in terms of major bleeding and GI bleeding, apixaban had the lowest bleeding risk; in terms of intracranial bleeding, rivaroxaban had the lowest bleeding risk; in terms of fatal bleeding, edoxaban had the lowest bleeding risk. For the prevention of VTE, apixaban had the lowest bleeding risk.
引用
- Chen J, Lv M, Wu S, et al. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2021. PMID: 34973879. doi:10.1016/j.ejvs.2021.10.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。